Werfen to acquire Omixon expanding its portfolio in transplant diagnostics

Barcelona, Spain May 15, 2024.- Werfen announced today that it has agreed to acquire Omixon, a privately held corporation with an innovative portfolio in transplant diagnostics headquartered in Budapest, Hungary. The acquisition will allow Werfen to expand its portfolio of transplant diagnostics solutions for hospitals and clinical laboratories.

 

Read more

Omixon at EFI 2024 Geneva

Excitement is building as we gear up for this year’s EFI Conference in Geneva. Year after year EFI serves as a dynamic platform for exchanging ideas, networking, and exploring collaborations that can drive the field forward. Be sure to visit the Omixon booth first to see NanoTYPE and NanoTYPER...

 

Read more

Omixon at EFI 2023

We are happy to announce that Omixon will attend the 36th European Immunogenetics & Histocompatibility Conference in Nantes on 26-29 April 2023. The theme of the conference this year will be Big Data in Immunogenetics at The Crossroad of Care, Tools & Research. Visit the Omixon Booth #5 and...

 

Read more

Omixon Launches NanoTYPETM RUO, a Multiplex Human Leukocyte Antigen Amplification kit compatible with Oxford Nanopore’s MinIONTM Platform and Enters into an Agreement with Oxford Nanopore Technologies

High resolution histocompatibility testing for urgent transplant cases made possible within five hours turnaround time. Budapest, Hungary, September 27, 2022. Omixon Biocomputing, Ltd announced today the launch of NanoTYPETM RUO, a multiplex 11 loci human leukocyte antigen (HLA) amplification kit and the complementary NanoTYPERTM software compatible with Oxford Nanopore’s...

 

Read more